R. Porta

Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation

R. Porta, J.M. Sánchez-Torres, Luis Paz‐Ares et al. · European Respiratory Journal · 2010 · 316 citations · Full text

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Advanced Nsclc P, Medicine, Phase Iii +14

Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial

Bartomeu Massutí, Teresa Morán, R. Porta et al. · Journal of Clinical Oncology · 2009 · 17 citations

Advanced Nsclc P, Customized Erlotinib, Medicine +13

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

R. Rosell, Matias Molina, Camila Mendes Costa et al. · Journal of Clinical Oncology · 2010 · 14 citations

High Brca1, Intermediate Brca1, Pretreatment Biopsies +15

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Porta, Cristina Queralt, F. Cardenal et al. · Journal of Clinical Oncology · 2008 · 10 citations